Metabolically Armed CD19 CAR-T cells(Leman Biotech)

抗CD19 CAR-T细胞疗法（莱芒生物）

Report date: 2026/03/18 16:49:42

Base Information

Drug NameMetabolically Armed CD19 CAR-T cells(Leman Biotech)
Drug Alias NameMeta10-19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicHematologic NeoplasmsLymphoma, Mantle-Cell +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLeman Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLeman Biotech Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicHematologic NeoplasmsLymphoma, Mantle-Cell +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A